Literature DB >> 24846408

N-(2-hydroxy phenyl) acetamide: a novel suppressor of Toll-like receptors (TLR-2 and TLR-4) in adjuvant-induced arthritic rats.

Kahkashan Perveen1, Farina Hanif, Huma Jawed, Siddiqua Jamall, Shabana Usman Simjee.   

Abstract

Toll-like receptors (TLRs) are key recognition structures of immune system and recently emerged as potential contributors to the inflammation observed in human and rodent models of arthritis. Present study aims to investigate the effect of N-(2-hydroxy phenyl)-acetamide (NA-2) on modulation of TLRs in the development of adjuvant-induced arthritis. Arthritis was induced by intradermal administration of heat-killed Mycobacterium tuberculosis H37Ra. The treatment of NA-2 (5 mg/kg) and indomethacin (5 mg/kg) was started in their respective group on the day of arthritis induction. Body weights, paw volume measurements, and nociception sensation (Plantar test) were done on alternate days to monitor the progression of the disease until arthritis score of four was observed in arthritic control group. Along with the clinical signs, histopathology of knee joints was also performed. The splenocytes cultures were prepared from each group; TLR-2 and TLR-4 mRNAs were analyzed in 48-h cultured splenocytes using RT-PCR; and the supernatants were used to determine IL-1β and TNF-α by ELISA. A significant reversal of deficit seen in body weights of the arthritic control group was observed in NA-2-treated animals with a parallel decrease in paw edema and transmission of nociception. Remission of the clinical signs and nociception was associated with improved histology. Compared with arthritic control, NA-2 treatment significantly decreased the level of IL-1β (p < 0.003) and TNF-α (p < 0.001) in the supernatants of cultured splenocytes. Likewise, NA-2 also reduced the expression of TLRs mRNA. Our findings suggest that NA-2 affects AIA in a pleiotropic manner, suppressing TLRs-mediated joint inflammation and related symptoms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24846408     DOI: 10.1007/s11010-014-2082-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  42 in total

1.  Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4.

Authors:  Geoffrey B Johnson; Gregory J Brunn; Yuzo Kodaira; Jeffrey L Platt
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

Review 2.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

3.  Acetabular bone destruction related to non-steroidal anti-inflammatory drugs.

Authors:  N M Newman; R S Ling
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

4.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

Review 5.  Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.

Authors:  J Meyer-Kirchrath; K Schrör
Journal:  Curr Med Chem       Date:  2000-11       Impact factor: 4.530

6.  Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4.

Authors:  Alexzander Asea; Michael Rehli; Edith Kabingu; Jason A Boch; Olivia Bare; Philip E Auron; Mary Ann Stevenson; Stuart K Calderwood
Journal:  J Biol Chem       Date:  2002-02-08       Impact factor: 5.157

Review 7.  Pain and osteoarthritis: new drugs and mechanisms.

Authors:  Burkhard Hinz; Kay Brune
Journal:  Curr Opin Rheumatol       Date:  2004-09       Impact factor: 5.006

Review 8.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

9.  Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium.

Authors:  Reinhart Seibl; Thomas Birchler; Susanne Loeliger; Johann Peter Hossle; Renate E Gay; Traudl Saurenmann; Beat A Michel; Reinhard A Seger; Steffen Gay; Roger P Lauener
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

10.  Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide.

Authors:  François Coulombe; Maziar Divangahi; Frédéric Veyrier; Louis de Léséleuc; James L Gleason; Yibin Yang; Michelle A Kelliher; Amit K Pandey; Christopher M Sassetti; Michael B Reed; Marcel A Behr
Journal:  J Exp Med       Date:  2009-07-06       Impact factor: 14.307

View more
  3 in total

1.  N-(2-Hydroxyphenyl)acetamide: a Novel Suppressor of RANK/RANKL Pathway in Collagen-Induced Arthritis Model in Rats.

Authors:  Anum Gul; Bimal Kunwar; Maryam Mazhar; Kahkashan Perveen; Shabana U Simjee
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

2.  TLR-2-mediated metabolic reprogramming participates in polyene phosphatidylcholine-mediated inhibition of M1 macrophage polarization.

Authors:  Ting-Ting Feng; Xiao-Ying Yang; Shan-Shan Hao; Fen-Fen Sun; Ye Huang; Qi-Si Lin; Wei Pan
Journal:  Immunol Res       Date:  2020-02       Impact factor: 2.829

Review 3.  Emerging medical therapies in crush syndrome - progress report from basic sciences and potential future avenues.

Authors:  Ning Li; Xinyue Wang; Pengtao Wang; Haojun Fan; Shike Hou; Yanhua Gong
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.